文献速递流行病学与生物统计临床试验与 GCP新药、器械与细胞基因治疗研发

筛查不健康药物使用:美国预防服务工作组更新证据报告与系统综述

Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2020-01-01

该系统综述纳入99项研究(N=84 206),评估药物使用筛查工具的准确性及干预效果。成人筛查工具敏感度0.71–0.94、特异度0.87–0.97;心理社会干预可提高戒断率(RR 1.60)并减少使用天数,阿片激动剂与纳曲酮可降低复发风险。尚无筛查本身获益或危害的直接证据。

要点

  • 成人药物使用筛查工具敏感度0.71–0.94、特异度0.87–0.97,但筛查获益与危害无直接证据。
  • 心理社会干预提高戒断可能性(RR 1.60)并减少药物使用天数。
  • 在求治人群中,阿片激动剂和纳曲酮降低复发风险,严重不良事件风险未增加。

核心结论

  • 多种筛查工具敏感度和特异度可接受,但筛查本身获益或危害缺乏直接证据。
  • 药物疗法和心理社会干预可改善药物使用结局,证据主要来自求治人群试验。

研究设计与样本

  • 系统综述纳入99项研究(N=84 206),检索MEDLINE、PubMed、PsycINFO、Embase和Cochrane Central截至2018年9月18日,文献监测至2019年9月21日。
  • 纳入筛查工具准确性研究和随机临床试验,由2名评价员独立评估,采用随机效应荟萃分析。

主要发现

  • 心理社会干预 vs 无干预:戒断RR 1.60(95%CI 1.24–2.13),ARD 9%(95%CI 5%–15%);减少使用天数MD -0.49天/过去7天(95%CI -0.85至-0.13)。
  • 求治人群中,阿片激动剂 vs 安慰剂/无药物:复发RR 0.75(95%CI 0.59–0.82),ARD -35%(95%CI -67%至-3%);纳曲酮 vs 安慰剂/无药物:复发RR 0.73(95%CI 0.62–0.85),ARD -18%(95%CI -26%至-10%)。
  • 危害证据有限,但未显示严重不良事件风险增加。

关键数值与推荐

  • 成人筛查工具敏感度0.71–0.94、特异度0.87–0.97。
  • 心理社会干预提高戒断可能性(RR 1.60,95%CI 1.24–2.13)。
  • 阿片激动剂降低复发风险(RR 0.75,95%CI 0.59–0.82)。
  • 纳曲酮降低复发风险(RR 0.73,95%CI 0.62–0.85)。

临床怎么用

  • 可选用敏感度和特异度可接受的工具筛查不健康药物使用,但需知筛查获益与危害证据不足。
  • 对求治人群,阿片激动剂和纳曲酮可降低复发风险,心理社会干预可提高戒断率并减少使用天数。

局限性

  • 筛查本身获益或危害缺乏直接证据。
  • 干预有效性证据主要来自求治人群试验。
  • 危害证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Illicit drug use is among the most common causes of preventable morbidity and mortality in the US. OBJECTIVE: To systematically review the literature on screening and interventions for drug use to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed, PsycINFO, Embase, and Cochrane Central Register of Controlled Trials through September 18, 2018; literature surveillance through September 21, 2019. STUDY SELECTION: Test accuracy studies to detect drug misuse and randomized clinical trials of screening and interventions to reduce drug use. DATA EXTRACTION AND SYNTHESIS: Critical appraisal and data abstraction by 2 reviewers and random-effects meta-analyses. MAIN OUTCOMES AND MEASURES: Sensitivity, specificity, drug use and other health, social, and legal outcomes. RESULTS: Ninety-nine studies (N = 84 206) were included. Twenty-eight studies (n = 65 720) addressed drug screening accuracy. Among adults, sensitivity and specificity of screening tools for detecting unhealthy drug use ranged from 0.71 to 0.94 and 0.87 to 0.97, respectively. Interventions to reduce drug use were evaluated in 52 trials (n = 15 659) of psychosocial interventions, 7 trials (n = 1109) of opioid agonist therapy, and 13 trials (n = 1718) of naltrexone. Psychosocial interventions were associated with increased likelihood of drug use abstinence (15 trials, n = 3636; relative risk [RR], 1.60 [95% CI, 1.24 to 2.13]; absolute risk difference [ARD], 9% [95% CI, 5% to 15%]) and reduced number of drug use days (19 trials, n = 5085; mean difference, -0.49 day in the last 7 days [95% CI, -0.85 to -0.13]) vs no psychosocial intervention at 3- to 4-month follow-up. In treatment-seeking populations, opioid agonist therapy and naltrexone were associated with decreased risk of drug use relapse (4 trials, n = 567; RR, 0.75 [95% CI, 0.59 to 0.82]; ARD, -35% [95% CI, -67% to -3%] and 12 trials, n = 1599; RR, 0.73 [95% CI, 0.62 to 0.85]; ARD, -18% [95% CI, -26% to -10%], respectively) vs placebo or no medication. While evidence on harms was limited, it indicated no increased risk of serious adverse events. CONCLUSIONS AND RELEVANCE: Several screening instruments with acceptable sensitivity and specificity are available to screen for drug use, although there is no direct evidence on the benefits or harms of screening. Pharmacotherapy and psychosocial interventions are effective at improving drug use outcomes, but evidence of effectiveness remains primarily derived from trials conducted in treatment-seeking populations.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Patnode CD, Perdue LA, Rushkin M, et al. Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 32515820. doi:10.1001/jama.2019.21381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。